Eliot Brinton
Endocrinology, Diabetes & Metabolism · Salt Lake City, UTNPI 1033209614
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $497,319 of the $733,495 with a category attached, or 67.8%. 30 manufacturers reported payments, led by Amarin Pharma, Inc. at 33.6% of the total. Reporting peaked in 2019 at $231,900 and has fallen 59.0% since, to $95,150 in 2025. Among endocrinology, diabetes & metabolism clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,041 payments — averaging $704.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$246K
- Esperion Therapeutics, Inc.$116K
- Amgen$114K
- Amryt Pharma Holdings Ltd$51K
- Madrigal Pharmaceuticals$41K
- Regeneron Healthcare Solutions, Inc.$38K
- plus $128K from 24 others
Across 28 payments — averaging $3265.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$91K
What the payments were for
- Consulting fees$96,46813%
- Speaking & faculty fees$497,31968%
- Travel & lodging$121,74517%
- Food & beverage$17,6182%
- Education$3460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 393 | $246,257 |
| Esperion Therapeutics, Inc. | 109 | $116,323 |
| Amgen | 210 | $113,643 |
| Amryt Pharma Holdings Ltd | 40 | $51,475 |
| Madrigal Pharmaceuticals | 55 | $40,548 |
| Regeneron Healthcare Solutions, Inc. | 46 | $37,664 |
| Kaneka Medical America LLC | 5 | $31,463 |
| Chiesi USA, Inc. | 28 | $21,074 |
| GSK | 14 | $12,654 |
| Mirum Pharmaceuticals, Inc. | 9 | $12,366 |
| Novartis | 19 | $8,533 |
| Regeneron | 18 | $8,321 |
| Kowa Research Institute, Inc. | 9 | $5,837 |
| CSL Behring | 2 | $4,885 |
| Novo Nordisk | 33 | $4,578 |
| Sanofi-aventis U.S. LLC | 10 | $3,545 |
| Pfizer | 1 | $3,148 |
| Medicure Pharma Inc. | 2 | $2,750 |
| AstraZeneca | 6 | $2,677 |
| Ionis Pharmaceuticals, Inc. | 3 | $2,499 |
| Merck | 11 | $2,275 |
| Bayer | 5 | $224 |
| Agepha Pharma FZ LLC | 1 | $183 |
| Kowa Pharmaceuticals America, Inc. | 2 | $178 |
| Janssen Scientific Affairs, LLC | 2 | $152 |
| Corcept Therapeutics | 3 | $133 |
| Johnson & Johnson | 1 | $40 |
| Lilly USA, LLC | 1 | $31 |
| Boehringer Ingelheim | 2 | $30 |
| Aegerion Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$241,880
- NEXLETOL$115,418
- NEXLIZET$115,279
- Repatha$111,093
- JUXTAPID$71,592
- REZDIFFRA$38,766
- EVKEEZA$36,701
- LIPOSORBER$31,067
- Livmarli$9,586
- PRALUENT$7,867
- LEQVIO$7,140
- SHINGRIX$7,025
- DISEASE STATE$3,276
- CTEXLI$2,780
- EPANOVA$2,617
- TRYNGOLZA$2,480
- HMG-CoA reductase inhibitor.$2,250
- ZYPITAMAG (pitavastatin)$500
- LODOCO$183
- Kerendia$146
How this compares
$733,495 in reported general payments places this provider in the 95th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
See all endocrinology, diabetes & metabolism providers in Utah →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 13 | $14,311 |
| VascepaIcosapent Ethyl | 14 | $14,014 |
| Repatha SyringeEvolocumab | 11 | $5,529 |
| Ezetimibe | 24 | $322 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $260 |
| Rosuvastatin Calcium | 15 | $257 |
| Atorvastatin Calcium | 28 | $223 |
| Pioglitazone Hcl | 23 | $173 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Salt Lake City
- Alireza Falahati-NiniSalt Lake City$241K
- Shahzad AhmadSalt Lake City$25K
- Vishnu SundareshSalt Lake City$18K
- Bruce BradySalt Lake City$5K
- Barry BenowitzSalt Lake City$4K
- Marie CouldwellSalt Lake City$3K
- Kelsey DesalvoSalt Lake City$3K
- Sneha WagleSalt Lake City$257
- Javier Munoz BarreraSalt Lake City$160
- Ross HeinrichSalt Lake City$122
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.